Stoke Therapeutics CEO to Present at Needham Healthcare Conference
Event summary
- Stoke Therapeutics CEO Ian F. Smith to present at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, at 3:00 p.m. ET.
- Zorevunersen, Stoke's lead investigational medicine for Dravet syndrome, is in Phase 3 trials.
- Zorevunersen has received orphan drug designation from FDA and EMA, as well as Breakthrough Therapy Designation from FDA.
- Stoke has a strategic collaboration with Biogen for the development and commercialization of zorevunersen.
The big picture
Stoke Therapeutics' focus on RNA medicine and its proprietary TANGO approach positions it in the growing field of genetic therapies. The strategic partnership with Biogen underscores the potential of zorevunersen, particularly in the treatment of rare neurological disorders like Dravet syndrome. The upcoming conference presentation will provide insights into the company's progress and future plans in this competitive landscape.
What we're watching
- Clinical Progress
- The pace at which zorevunersen advances through Phase 3 trials will determine its market potential.
- Regulatory Dynamics
- Whether the FDA and EMA designations will expedite approval and commercialization efforts.
- Partnership Strategy
- How the collaboration with Biogen will impact global market access and revenue sharing.
Our editorial coverage:
Related topics